UNSPSC 51263108: Betaxolol or levobetaxolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0ZR1R6RZ2, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)- but generally known as betaxolol, which bears US NIH Compound Identifier 2369. Betaxolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Betaxolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05804MIG.

UNSPSC 51263108 Betaxolol or levobetaxolol is a Commodity code covering pharmaceutical products, but recent state and local procurement activity under this code shows little alignment with the nominal scope. The two recent opportunities posted to this code are for naloxone and drug deactivation systems (Seminole County, Florida) and a therapeutic pharmacy initiative direct-to-manufacturer prescriptions program (Texas Health and Human Services Commission), neither of which involves betaxolol or levobetaxolol. The mismatch suggests either miscoding at the issuing body or that state and local procurement offices are applying this code more broadly to pharmaceutical procurement categories than the UNSPSC taxonomy intends. Activity under the code is sparse and geographically scattered across Florida and Texas, with no pattern of repeat buyers or concentrated solicitation activity.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023, on a fixed-fee basis with an initial two-year term and optional one-year renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no formal evaluation criteria, award value, or binding timeline. Neither opportunity targets betaxolol or levobetaxolol specifically. Given the limited recent activity and the clear disconnect between the code's nominal pharmaceutical scope and actual solicitations, this code warrants monitoring for clearer activity patterns rather than active pursuit at this time.